Material and Supplier Changes to 510(k)-Cleared Devices: New 510(k) Triggers and FDA Testing Expectations

Material and supplier changes to 510(k)-cleared devices: when a new 510(k) is required and what testing FDA expects

A material or supplier change to a 510(k)-cleared device does not automatically require a new 510(k). The legal trigger is whether the change could significantly affect the device's safety or effectiveness, and FDA's 2017 final guidance on device changes turns that standard into a stepwise materials analysis built on biocompatibility risk, prior use of the same finished material, and performance impact ⁸⁸¹⁹⁹³². Where a new submission is needed, FDA's final ISO 10993-1 guidance sets the evidentiary expectations, and its draft chemical-analysis guidance (not for implementation) shows where chemical characterization recommendations are heading ²³³²³².

The regulatory trigger: 21 CFR 807.81(a)(3)

Under 21 CFR 807.81(a)(3), a premarket notification is required when a device already in commercial distribution "is about to be significantly changed or modified in design, components, method of manufacture, or intended use." The regulation lists two categories of significant change ⁸⁸:

A change "that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process" ⁸⁸.
A major change or modification in the intended use of the device ⁸⁸.

The notification must be submitted at least 90 days before the changed device is introduced into interstate commerce, subject to the exceptions in 807.81(b) ⁸⁹. Submitting on time is not authorization: the changed device should not be commercially distributed until FDA issues a substantial-equivalence order.

The regulation names material and chemical composition explicitly, but the operative word is "could." FDA's guidance treats the question as whether a change could significantly affect safety or effectiveness, positively or negatively, not whether it was intended to ⁷²²⁶. A change made with the intent to significantly affect safety or effectiveness (for example, to mitigate a known risk) requires a new 510(k) ⁷².

Principles that govern every change assessment

The guidance Deciding When to Submit a 510(k) for a Change to an Existing Device (final, October 2017) ¹⁹⁹ applies several principles that shape any material or supplier decision:

Risk assessment comes first. Manufacturers should identify new risks, changes to existing risks, and unintended consequences, considering effectiveness as well as safety ⁷³⁷⁴. New or significantly modified risks generally make a new 510(k) likely, and a significant risk can require submission even if it can be mitigated ⁷⁵⁷⁶.
Verification and validation confirm the decision, they do not override it. A "no 510(k)" decision should be confirmed by successful routine verification and validation. Unexpected results, unmet acceptance criteria, or inadequate routine methods require reassessment and may make a new 510(k) likely ⁷⁷⁷⁸. Passing tests does not remove the obligation to submit when the risk assessment already shows the change could significantly affect safety or effectiveness ⁷⁹.
Cumulative changes count. Changes are assessed individually and together, against the most recently cleared device rather than the last unsubmitted version ⁸⁰.
Document the rationale. Device changes and the 510(k) decision rationale must be documented under the quality system ⁸¹.

Supplier changes: not an automatic trigger

FDA does not treat a change of material supplier as a per se 510(k) trigger. The guidance directs the manufacturer to use its quality-system process to determine what has actually changed, even where the supplied material stays within its original specifications ³². Changes to a supplier's processing or finishing steps also require evaluation, because finished-device properties depend on manufacturing and sterilization processes and residuals, not only on the nominal raw material ³²³³.

In practice, this means a supplier change is analyzed as a potential change in material type, formulation, chemical composition, or processing. If the analysis shows such a change, the manufacturer proceeds through the materials decision path described below ³²¹⁹⁵.

Under current Part 820, the quality-system framework for this evaluation flows through ISO 13485:2016, which 21 CFR 820.7 incorporates by reference; 820.10(c) requires class II and III manufacturers (and specified class I manufacturers) to comply with ISO 13485 Clause 7.3 on design and development ²⁶⁰²⁶¹. A supplier change, even one within specification, is also handled through ISO 13485 Clause 7.4 purchasing and supplier controls and the manufacturer's change-control and records procedures.

The materials decision path for non-IVD devices

For non-IVD devices, the guidance's materials flowchart asks a sequence of questions. Labeling, design, and performance effects of the material change must be evaluated alongside it ³⁰³¹.

Step	Question	Outcome
C2	Did the material type, formulation, chemical composition, or processing change (including supplier or in-house processing and finishing)?	If no, document; a new 510(k) is unlikely on materials grounds ³²³⁴
C3	Will the changed material directly or indirectly contact body tissues or fluids (patient or user)?	If yes, go to C4; if no, go to C5 ³⁵³⁶
C4	Does a risk assessment identify new or increased biocompatibility concerns?	If no, go to C5; if yes, go to C4.1 ³⁷³⁸
C4.1	Has the manufacturer used the same material, in its final finished state, in a similar legally marketed device?	If no, a new 510(k) is likely; if yes, go to C5 ³⁹⁴⁰
C5	Could the change affect performance specifications?	If yes, go to design-change question B5; if no, document ⁴²⁴³

FDA's examples clarify each step:

Type and formulation changes. Latex to synthetic rubber is a material type change. A move from series 300 to series 400 stainless steel, or adding a compound to a polymer, is a formulation change ³⁴.
Indirect contact. A catheter hub has indirect patient contact when infused fluid passes through it, while hermetically sealed internal components of a spinal cord stimulator do not contact the patient ³⁶.
New biocompatibility concerns. Examples include a newly needed implantation test and a new chemical component that raises a genotoxicity concern ³⁸.
"Same material" is a strict comparison. The comparison covers formulation, processing, and sterilization, plus contact type and duration. The prior device should have the same or riskier contact and the same or longer duration. Differences in geometry, surface properties, joining, or use may defeat the comparison ³⁹⁴⁰. Another manufacturer's device ordinarily is not an adequate comparator unless its exact formulation and processing can be verified ⁴¹.

Examples where FDA indicates a new 510(k) is likely

A catheter switched to a polymer the manufacturer has not used before. Knowing that a competitor markets a catheter in that polymer does not establish identical formulation or processing ⁴⁴.
The manufacturer's prior use of the material involved only limited skin contact, but the modified catheter will have prolonged blood contact ⁴⁵.
The manufacturer previously used the material with different processing, such as extrusion rather than molding, or a different sterilization process ³.
Acid-etching a dental implant, which introduces a potential acid-residue biocompatibility risk through a process the manufacturer has not used ⁴⁶.

Examples where documentation to file suffices

The manufacturer's other cleared catheter uses the same polymer with the same formulation and processing, comparable contact, and the same performance specifications ⁴⁷⁴⁸.
Prior use involved riskier and longer contact than the proposed use, and performance is unaffected ⁴⁹.
A temporary manufacturing tape that leaves no adhesive residue and affects neither biocompatibility nor performance ⁵⁰.

If performance might be affected, documentation is possible only after the B5 assessment supports it; significantly different physical properties could instead call for a new 510(k) ⁵¹.

When a material change affects performance (question B5)

A material change that could affect performance specifications is routed to the B5 design-change questions ⁴²²⁵⁰. A new 510(k) is indicated if any of the following is true:

The change significantly affects how the device is used (B5.1) ²⁵¹.
A risk-based assessment identifies new risks or significantly modified existing risks (B5.2) ²⁵².
Clinical data are necessary to evaluate safety or effectiveness for design validation (B5.3) ²⁵³.
Design verification or validation produces unexpected safety or effectiveness issues (B5.4) ²⁵⁴.

For B5.4, routine verification and validation means the activities used to assess the original design, and the manufacturer should consider whether those methods and criteria are adequate for the changed device ⁷⁷.

Related manufacturing, sterilization, and site changes

Material and supplier changes often arrive bundled with process changes. The guidance notes that switching from machining to stamping may also change material grade and dimensional tolerances, requiring both materials and performance evaluations ¹⁸⁹.

For sterilization, switching from an established Category A method to a Category B or novel method generally requires a new 510(k), as does a reduction in sterility assurance level unless it remains better than 10⁻⁶ ¹⁹⁰¹⁹¹¹⁹². Changing a device between sterile and non-sterile supply is likely to require a new 510(k) ¹⁹³. Other sterilization method changes require assessment of whether performance or biocompatibility could be significantly affected ¹⁹⁴.

The guidance does not establish a site-change-only rule requiring a new 510(k); the manufacturing-change assessment applies to any resulting device changes ¹⁹⁷. FDA's separate site-change guidance addresses PMA supplements and does not apply to 510(k)-cleared devices ¹⁹⁸.

IVD material and reagent changes

For in vitro diagnostics, material changes, including reagent changes, are evaluated under the IVD-specific section of the guidance rather than the non-IVD materials flowchart ²²⁵²²⁶. A new 510(k) is likely when the change alters the operating principle in a way that could affect analyte detection, the value assigned to a specimen, or reported performance. Changes in antibodies, detection reagents, critical reaction components, and conjugates are listed as examples likely to alter the operating principle ²²⁸.

Even if the operating principle is unchanged, a new 510(k) is indicated where a device-specific guidance or classification regulation identifies the change, a risk assessment finds new or significantly modified risks, or verification and validation reveal unexpected issues ²²⁹. In one FDA example, a reagent-material change warranted a new 510(k) because it could shift the analytical cut-off enough to change diagnoses near that cut-off ²³⁰.

What testing FDA expects to support a material or supplier change

Whether the change ends in a file memo or a new 510(k), the evidence base is largely the same. The main difference is whether FDA reviews it.

Biocompatibility: a risk-based evaluation of the finished device

FDA's ISO 10993-1 guidance (final, September 2023) ²³³ calls for a risk-based evaluation of the final finished device rather than an assumption that a familiar material remains biocompatible after a change. The evaluation should consider the changed materials and formulation, manufacturing and sterilization, processing residuals, and the nature of clinical contact, and should identify available evidence, gaps, and the testing needed to close them. Physical and surface changes matter as well as chemical toxicity ¹⁵¹¹⁵².

Specific expectations by change type:

New raw-material supplier or specification. A new supplier can introduce different types or amounts of residual chemicals even when the base material has a long history of safe use. Comparative chemical characterization, together with incoming material or component specifications, can establish whether new or increased impurities could affect biocompatibility and whether further testing is needed ¹⁵³¹⁵⁴. Raw-material-level characterization can sometimes justify omitting device-level testing, but a resin change can also alter the finished device's physical or surface properties ¹⁵⁵.
Formulation changes. New chemicals such as surfactants, antioxidants, or plasticizers may require purity and impurity information, literature data, or additional toxicity testing for endpoints relevant to the contact type and duration. Interactions between the added chemical and the base material must be considered; data on each alone may be insufficient ¹⁵⁶¹⁵⁷.
Processing or sterilization changes. A sponsor relying on results from an existing test article or marketed device should identify the change and provide scientific information showing it does not alter the final device's chemical or physical properties, in enough detail for FDA to assess that conclusion independently ¹⁵⁸¹⁵⁹.

Biological endpoints

The relevant endpoints depend on material chemistry and on the nature, degree, frequency, and duration of contact, and not every endpoint necessarily requires a new test. Endpoints to consider include cytotoxicity, irritation, sensitization, systemic toxicity, hemocompatibility, implantation, genotoxicity, carcinogenicity, and reproductive or developmental toxicity, as applicable ¹⁶⁰. When testing is warranted, FDA recommends testing the device as used where possible. A representative test article should match the finished device's manufacturing, sterilization, chemical, physical, and surface characteristics, with any differences explained ¹⁶¹.

Leveraging prior data

A legally marketed device with comparable tissue exposure and material, plus an explanation of why manufacturing will not adversely affect biocompatibility, may support omitting some or all endpoint testing ¹⁶². The closer the devices are in intended use, formulation, and processing, the more applicable the prior experience ¹⁶³. Sponsors should compare materials specifically, identify the prior submissions and test reports relied on, and explain what gaps remain and why additional testing is or is not needed ¹⁶⁴¹⁶⁵.

Chemical characterization and toxicological risk assessment

Extractables and leachables analysis can show whether a device is chemically comparable to one with demonstrated biocompatibility, for example whether the extractables profile has changed after a material change. An unchanged profile may support a rationale that additional testing with that solvent is unnecessary ¹⁶⁵. Extraction conditions should be justified: solvents should be compatible with the materials and informative about chemicals likely to be released clinically, and solvents that swell, degrade, or dissolve the polymer should be used cautiously ¹⁷².

The toxicological risk assessment should address chemicals that may elute, together with relevant material information, and for a reformulation should consider the added chemical, the base material, and their interactions ¹⁷³¹⁵⁷. FDA cautions that chemical analysis alone does not establish overall biocompatibility, because it can miss risks from surface texture or geometry ¹⁷².

FDA's September 2024 draft guidance Chemical Analysis for Biocompatibility Assessment of Medical Devices (not for implementation) ²³² further describes chemical characterization as support for a TRA of systemic toxicity, genotoxicity, carcinogenicity, and reproductive or developmental endpoints, or for a chemical-equivalency comparison. If compatible extraction solvents cannot be identified, chemical data generally would not be appropriate to support a TRA, and other information such as biological testing may be needed ¹⁶⁷¹⁷⁴.

Performance testing

The guidance asks manufacturers to consider effects on mechanical properties and on labeled cleaning, disinfection, or sterilization when assessing whether a material change could affect performance ⁴²⁴³. Routine verification and validation methods from the original design must be adequate for the changed material, and unexpected results trigger reassessment of the 510(k) decision ⁷⁷²⁵⁴.

Submission pathway: when a Special 510(k) fits

Once a manufacturer concludes a new 510(k) is needed, a Special 510(k) may be appropriate if the manufacturer is modifying its own legally marketed device and either no performance data are needed or well-established methods are available, with any required data reviewable in summary or risk-analysis format ¹¹⁶¹¹⁷¹¹⁸. Well-established methods can include methods and acceptance criteria from the manufacturer's prior cleared 510(k), FDA-recognized standards or guidance, or other widely accepted methods, and all methods used should be well-established; significant deviations in protocol or acceptance criteria may make Special review inappropriate ¹¹⁹.

A Special 510(k) should include a tabular comparison of the modified and cleared devices, identification of the changes including material changes, and a concise design-control summary or risk analysis that states the risk-analysis method, risks and controls, verification and validation performed, adequacy of methods and acceptance criteria, and summarized results with descriptive statistics. Complete test reports should not be submitted as the basis of a Special 510(k) ⁹⁷¹²¹¹²². FDA's illustrative example of a sheath changed to polyethylene identifies adverse tissue reaction as a risk, applies a DFMEA and risk controls, and summarizes biocompatibility testing in a table ¹²³. That example does not mean every material change qualifies or needs the same tests ¹²³.

Practical takeaways

Treat any supplier change as a potential change in formulation, composition, or processing, and evaluate it through the quality system even when the material stays in specification ³².
For patient-contacting materials, the pivotal questions are whether the risk assessment shows new or increased biocompatibility concerns and whether the manufacturer has used the identical finished material in a similar device with equal or riskier contact ³⁷³⁹⁴⁰.
Competitor use of a material does not substitute for the manufacturer's own experience with the same formulation and processing ⁴¹⁴⁴.
Build the supporting evidence around comparative chemical characterization, a toxicological risk assessment, endpoint-specific biological testing where gaps remain, and performance verification against the original acceptance criteria ¹⁵³¹⁶⁰¹⁶⁵⁷⁷.
Document the decision and rationale, and assess cumulative changes against the most recently cleared device ⁸⁰⁸¹.